ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last2,701 to 2,720 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Folic Acid 4 mg vs Placebo: Composite Severe Adverse Fetal/Neonatal Outcome63 of 1,349

51 of 1,348

0.9 points

-0.6 to 2.4

2,697NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 2.4g IV18 of 1,355

62 of 1,341

-3.3 points

-4.6 to -2.0

2,696NCT04425629

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

Folic Acid 4 mg vs Placebo: Intrauterine Growth Restriction (<10th Percentile)151 of 1,347

144 of 1,348

0.5 points

-1.8 to 2.9

2,695NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Intrauterine Growth Restriction (<3rd Percentile)20 of 1,347

25 of 1,348

-0.4 points

-1.4 to 0.6

2,695NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Neonatal Intensive Care Unit (NICU) Admission299 of 1,346

267 of 1,348

2.4 points

-0.7 to 5.5

2,694NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Ventilation49 of 1,346

30 of 1,348

1.4 points

0.1 to 2.7

2,694NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Treatment - Participation in Nurse Family Partnership vs Control: Number of Participants With a Group B Streptococcus Test (35-37 Weeks)1,150 of 1,807

602 of 885

-4.4 points

-8.1 to -0.6

2,692NCT03360539

Nurse-Family Partnership Impact Evaluation in South Carolina

Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization or All-cause Death From Day 4 Through Day 29 (Ph3 Cohort 1 - 2.4g vs. Placebo)5 of 1,351

46 of 1,340

-3.1 points

-4.2 to -2.1

2,691NCT04425629

Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19

Folic Acid 4 mg vs Placebo: Necrotising Enterocolitis8 of 1,343

3 of 1,347

0.4 points

-0.1 to 1.0

2,690NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Neonatal Death8 of 1,343

11 of 1,347

-0.2 points

-0.9 to 0.5

2,690NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Intraventricular Hemorrhage (IVH)18 of 1,343

19 of 1,347

-0.1 points

-1.0 to 0.8

2,690NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Neonatal Death151 of 1,343

144 of 1,347

0.6 points

-1.8 to 2.9

2,690NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Periventricular Leukomalacia4 of 1,343

2 of 1,347

0.1 points

-0.3 to 0.6

2,690NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

SZC (Active) vs Placebo: Incidence of the Composite of Cardiac Event Outcomes119 of 1,349

119 of 1,341

-0.1 points

-2.2 to 2.1

2,690NCT04847232

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

SZC (Active) vs Placebo: Incidence of the Composite of Arrhythmia Related Events74 of 1,349

65 of 1,341

0.6 points

-1.0 to 2.3

2,690NCT04847232

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Folic Acid 4 mg vs Placebo: Retinopathy of Prematurity21 of 1,342

13 of 1,347

0.6 points

-0.3 to 1.5

2,689NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Folic Acid 4 mg vs Placebo: Early Onset Sepsis3 of 1,342

9 of 1,347

-0.4 points

-1.1 to 0.1

2,689NCT01355159

High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention

Adriamycin + Cyclophosphamide vs Fluorouracil + Epirubicin + Cyclophosphamide: serious adverse events12 of 1,351

26 of 1,337

-1.1 points

-2.0 to -0.2

2,688NCT00087178

Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer

SZC (Active) vs Placebo: deaths from any cause120 of 1,348

113 of 1,338

0.5 points

-1.7 to 2.6

2,686NCT04847232

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

SZC (Active) vs Placebo: serious adverse events521 of 1,348

503 of 1,338

1.1 points

-2.6 to 4.7

2,686NCT04847232

Effect of Sodium Zirconium Cyclosilicate on Arrythmia-related Cardiovascular Outcomes in Participants on Chronic Hemodialysis With Recurrent Hyperkalemia (DIALIZE-Outcomes)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=136"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=136

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT01355159-5e71a335",
        "title": "Folic Acid 4 mg vs Placebo: Composite Severe Adverse Fetal/Neonatal Outcome",
        "summary": "63 of 1349 against 51 of 1348; risk difference 0.9 points, 95% interval -0.6 to 2.4; NCT01355159, High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention",
        "record": "/library/comparisons/NCT01355159-5e71a335",
        "nct_id": "NCT01355159",
        "kind": "outcome",
        "participants": 2697,
        "risk_difference": {
          "value": 0.00886743229956028,
          "lower": -0.0064435535827067954,
          "upper": 0.024321257737997762
        },
        "group_1": "63 of 1,349",
        "group_2": "51 of 1,348",
        "difference": "0.9 points",
        "interval": "-0.6 to 2.4",
        "trial_title": "High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention"
      },
      {
        "id": "NCT04425629-eae26900",
        "title": "Phase 3 Cohort 1 (2.4g IV) >= 18 vs Phase 3 Cohort 1 (Placebo) >=18: Proportion of Participants With ≥1 COVID-19-related Hospitalization, Emergency Room Visit, or All-cause Death (Ph3 Cohort 1) - Placebo vs. 2.4g IV",
        "summary": "18 of 1355 against 62 of 1341; risk difference -3.3 points, 95% interval -4.6 to -2.0; NCT04425629, Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19",
        "record": "/library/comparisons/NCT04425629-eae26900",
        "nct_id": "NCT04425629",
        "kind": "outcome",
        "participants": 2696,
        "risk_difference": {
          "value": -0.03295002077537554,
          "lower": -0.046450914504385335,
          "upper": -0.020378297111250242
        },
        "group_1": "18 of 1,355",
        "group_2": "62 of 1,341",
        "difference": "-3.3 points",
        "interval": "-4.6 to -2.0",
        "trial_title": "Safety, Tolerability, and Efficacy of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies for the Treatment of Ambulatory Adult and Pediatric Patients With COVID-19"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=137",
  "request_id": "sTdyRE9Rt2tqcrrJ"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?